AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback